Synapse - Works

Results (5225)

Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151

Meeting Abstract

Suarez, C.; Choueiri, T. K.; McDermott, D. F.; Escudier, B.; Atkins, M. B.; Powles, T. B.; Rini, B. I.; Motzer, R. J.; Pal, S. K.; Fong, L.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients

Meeting Abstract

Specht, J.; Pusztai, L.; Forero-Torres, A.; Mita, M.; Weise, A.; Krop, I.; Grosse-Wilde, A.; Wang, Z.; Li, M.; Hengel, S.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial

Meeting Abstract

Sonnenblick, A.; Bailey, A.; Uziely, B.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Jackisch, C.; Cameron, D.; Bell, R.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214

Meeting Abstract

Rini, B. I.; Tannir, N. M.; Escudier, B.; McDermott, D. F.; Grimm, M. O.; Porta, C.; Powles, T.; Kollmannsberger, C. K.; Gurney, H. P.; Tykodi, S. S.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

EV-201: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy

Meeting Abstract

Rosenberg, J. E.; Balar, A.; O'Donnell, P. H.; Heath, E. I.; Hahn, N. M.; Cavazos, N. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
Annals of Oncology (2018)

Fulltext@MSK | Save

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032

Meeting Abstract

Rosenberg, J. E.; Sharma, P.; de Braud, F. G. M.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P. A.; Lopez-Martin, J. A.; Brossart, P.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

BAYOU: Phase II study of efficacy and safety of durvalumab plus olaparib as first-line therapy in cisplatin-ineligible patients (pts) with stage iv urothelial cancer (UC)

Meeting Abstract

Rosenberg, J. E.; Bajorin, D. F.; Smith, A.; D'Cruz, C.; Lanasa, M.
Annals of Oncology (2018)

Fulltext@MSK | Save

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

Meeting Abstract

Rudin, C. M.; Pandha, H. S.; Gupta, S.; Zibelman, M. R.; Akerley, W.; Day, D.; Hill, A. G.; Sanborn, R. E.; O'Day, S. J.; Clay, T. D.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)

Meeting Abstract

O'Cearbhaill, R. E.; Wolfer, A.; Disilvestro, P.; O'Malley, D. M.; Sabbatini, P.; Shohara, L.; Schwarzenberger, P. O.; Ricciardi, T.; Macri, M.; Ryan, A.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save

Tumour growth rate (TGR) when using lanreotide Autogel® (LAN) before, during and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumours (NETs)

Meeting Abstract

Prasad, V.; Srirajaskanthan, R.; Grana, C. M.; Baldari, S.; Shah, T.; Lamarca, A.; Courbon, F.; Scheidhauer, K.; Baudin, E.; Truong-Thanh, X. M.; more...
Annals of Oncology (2018)

Fulltext@MSK | Save